BI-1808
BI-1808 is a human IgG1 monoclonal antibody that targets TNFR2by blocking interaction of TNFR2 with ligand TNF-α, confers FcγR-dependent depletion of Treg and mediates expansion of intratumoral CD8+ T cells[1].
Product Specifications
UNSPSC
12352203
Target
TNF Receptor
Related Pathways
Apoptosis
Applications
Cancer-programmed cell death
Field of Research
Cancer
Purity
97.75
Molecular Weight
(144.206 kDa)
References & Citations
[1]Kristoffer Staahl Rohrberg1, et al. 757 Phase 1/2a clinical trial of BI-1808, a monoclonal antibody to tumor necrosis factor receptor 2 (TNFR2) as single agent and in combination with pembrolizumab. J Immunother Cancer 2023;11 (Suppl 1) :A1–A1731
Shipping Conditions
Dry Ice
Storage Conditions
-80°C
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 2
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
